RUNX2 and breast carcinoma: This is also supported by data from the METABRIC study, where 14% of primary breast cancer samples were found to harbor alterations in CBFB, while 11%, 5% and 4% of patient samples possessed various categories of genetic alterations in RUNX1, RUNX2 and RUNX3, respectively [24] (Figure 1A).